logo

For the Inventor, By the Inventor

Lexington, KY, United States of America

Jurgen Rohr

This inventor holds 7 USPTO granted patents and 1 published patent application. Top assignees: University of Kentucky Research Foundation, The University of Oviedo. Active years: 2008-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jurgen Rohr. Retrieved from https://idiyas.com/inventor/jurgen-rohr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 71.4

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 20(Granted Patents)


Location History:

  • Georgetown, KY (US) (2008 - 2010)
  • Lexington, KY (US) (2016 - 2023)

Company Filing History:

goldMedal7 out of 903 
 
University of Kentucky Research Foundation
 patents
silverMedal1 out of 12 
 
The University of Oviedo
 patents
where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...
7 patents (USPTO):Explore Patents
1. 12486300 - MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY (2025-12-02),
2. 11692003 - Mithramycin derivatives having increased selectivity and anti-cancer activity (2023-07-04),
3. 11466045 - Mithramycin oxime derivatives having increased selectivity and anti-cancer activity (2022-10-11),
4. 11224609 - Mithramycin derivatives having increased selectivity and anti-cancer activity (2022-01-18),
5. 9447135 - Semi-synthetic mithramycin derivatives with anti-cancer activity (2016-09-20),
6. 7799904 - Gilvocarcin gene cluster, recombinant production and use thereof (2010-09-21),
7. 7423008 - Derivatives of mithramycin and methods of making and uses thereof (2008-09-09),

Title: Jurgen Rohr: Innovator in Cancer Treatment

Introduction

Jurgen Rohr is a notable inventor based in Lexington, KY (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of mithramycin derivatives. With a total of 7 patents, his work focuses on enhancing the selectivity and anti-cancer activity of these compounds.

Latest Patents

Rohr's latest patents include the development of mithramycin derivatives that exhibit increased selectivity and anti-cancer activity. These derivatives, specifically mithramycin short side chain ketone (SK) and diketone (SDK) derivatives, are designed for the treatment of cancer and neuro-diseases associated with aberrant erythroblast transformation-specific transcription factor. The unique properties of these derivatives allow for increased selectivity toward ETS transcription factors. Additionally, he has developed mithramycin oxime derivatives and mithramycin hydrazine derivatives, which are also aimed at treating cancers and neuro-diseases.

Career Highlights

Throughout his career, Jurgen Rohr has worked with esteemed institutions such as the University of Kentucky Research Foundation and Universidad De Oviedo. His research has been pivotal in advancing the understanding and treatment of various cancers.

Collaborations

Rohr has collaborated with notable colleagues, including Markos Leggas and Oleg Tsodikov, contributing to a rich exchange of ideas and innovations in his field.

Conclusion

Jurgen Rohr's contributions to cancer treatment through his innovative patents and collaborations highlight his commitment to advancing medical science. His work continues to pave the way for new therapeutic options in the fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…